Professor Ammar Al-Chalabi is head of the Basic and Clinical Neuroscience Department at King’s College London, and Director of the King’s Motor Neuron Disease Care and Research Centre, a facility that includes our ALS clinic and laboratory and clinical research teams. He leads a group focussed on understanding what causes ALS, what might control the age it starts, and how fast it progresses.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.